Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Autophagy in Obesity and Type 2 Diabetes: Beyond the Protective Paradigm

Angarita-Plánchez ME., Sánchez-Rodríguez P., Múnera-Rodríguez AM., Leiva-Castro C., Benítez-Márquez JM., Reina-Pérez I.

Narrative Review on Type 2 Diabetes, published in Curr Obes Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Obes Rep (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42101776
PMCID
PMC13156086
DOI
10.1007/s13679-026-00716-5
Citations
1

Abstract (original English)

Purpose of review This review examines the current evidence on autophagy dysregulation in obesity and type 2 diabetes mellitus (T2DM), with particular emphasis on its tissue-specific nature and implications for clinical translation. Recent findings Recent human and preclinical evidence indicates that autophagic alterations in metabolic disease are not uniformly suppressed but vary according to tissue type and disease stage. In adipose tissue, liver, skeletal muscle, pancreatic β cells, and immune cells, dysregulated mTORC1-AMPK signaling, defective mitophagy, and impaired lysosomal function contribute to insulin resistance, ectopic lipid accumulation, and metaflammation. However, most human studies rely on static markers such as LC3, p62, and Beclin-1, which do not reliably reflect dynamic autophagic flux. Recent advances, including organelle-specific biomarkers, ex vivo functional assays, and circulating exosomal cargo, offer new translational opportunities, although standardization remains limited. Autophagy in metabolic disease represents a context-dependent maladaptation rather than a uniformly protective pathway. Future progress will depend on harmonized biomarker panels, functional assessment of autophagic flux in humans, and integration with metabolic phenotyping to enable precision-based therapeutic strategies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Muscle, SkeletalAdipose TissueAnimalsHumansDiabetes Mellitus, Type 2Insulin ResistanceObesitySignal TransductionAutophagyBiomarkers

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research